<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05009810</url>
  </required_header>
  <id_info>
    <org_study_id>EC2103320</org_study_id>
    <nct_id>NCT05009810</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Astaxanthin in Volunteer With Refraction Errors</brief_title>
  <official_title>Efficacy and Safety of Astaxanthin in Volunteer With Refraction Errors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate efficacy and safety of astaxanthin in 180 volunteers with&#xD;
      refraction errors. Visual test, skin test, liver function test, renal function test, and&#xD;
      adverse event will be evaluated before and after taking astaxanthin for 1 and 2 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate efficacy and safety of astaxanthin in 180 volunteers with&#xD;
      refraction errors. They will divided into 3 groups which are astaxanthin 4 mg group ,&#xD;
      astaxanthin 6 mg group, and placebo group. They will take the sample 1 capsule once daily for&#xD;
      2 months. Visual test, skin test, liver function test, renal function test, and adverse event&#xD;
      will be evaluated before and after taking the sample for 1 and 2 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual acuity value</measure>
    <time_frame>2 months</time_frame>
    <description>Measured using Snellen Chart (logarithm of the minimal angle of resolution unit)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Refractive status</measure>
    <time_frame>2 months</time_frame>
    <description>Measured using Auto refractometer (two digit scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eye fatigue status</measure>
    <time_frame>2 months</time_frame>
    <description>Measured using eye fatigue questionnaire (scale 1 to 5 which are no symptom (1) to severe(5))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vision status</measure>
    <time_frame>2 months</time_frame>
    <description>Measured using Thai National Eye Institute Visual Functioning Questionnaire 25 (scale 25 to 100 which are normal (25) to worse(100))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin erythema value</measure>
    <time_frame>2 months</time_frame>
    <description>Measured using Mexameter (skin erythema index)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin melanin value</measure>
    <time_frame>2 months</time_frame>
    <description>Measured using Mexameter (skin melanin index)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin humidity value</measure>
    <time_frame>2 months</time_frame>
    <description>Measured using Corneometer (skin humidity index)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin transepidermal water loss value</measure>
    <time_frame>2 months</time_frame>
    <description>Measured using Transepidermal water loss meter (skin transepidermal water loss index)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate transaminase value</measure>
    <time_frame>2 months</time_frame>
    <description>Measured aspartate transaminase value (U/L) in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine aminotransferase value</measure>
    <time_frame>2 months</time_frame>
    <description>Measured alanine aminotransferase value (U/L) in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline phosphatase value</measure>
    <time_frame>2 months</time_frame>
    <description>Measured alkaline phosphatase value (U/L) in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood urea nitrogen value</measure>
    <time_frame>2 months</time_frame>
    <description>Measured blood urea nitrogen value (mg/dl) in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine value</measure>
    <time_frame>2 months</time_frame>
    <description>Measured creatinine value (mg/dl) in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 months</time_frame>
    <description>Measured using questionnaire (Yes or No)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Refractive Errors</condition>
  <arm_group>
    <arm_group_label>astaxanthin 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The astaxanthin 4 mg will be taken 1 capsule once daily for 2 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>astaxanthin 6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The astaxanthin 6 mg will be taken 1 capsule once daily for 2 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo will be taken 1 capsule once daily for 2 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>astaxanthin 4 mg</intervention_name>
    <description>They will take astaxanthin 4 mg 1 capsule once daily for 2 months.</description>
    <arm_group_label>astaxanthin 4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>astaxanthin 6 mg</intervention_name>
    <description>They will take astaxanthin 6 mg 1 capsule once daily for 2 months.</description>
    <arm_group_label>astaxanthin 6 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>They will take placebo 1 capsule once daily for 2 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-65 years&#xD;
&#xD;
          -  Refraction errors, dry eye, or blurred vision&#xD;
&#xD;
          -  Have a willingness to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled disease&#xD;
&#xD;
          -  Have complications during the study&#xD;
&#xD;
          -  Have astaxanthin more than 2 weeks&#xD;
&#xD;
          -  Allergic to astaxanthin, seafood, or seaweed&#xD;
&#xD;
          -  Osteoporosis or thyroid disease&#xD;
&#xD;
          -  Immunodeficiency or taking immunosuppressants&#xD;
&#xD;
          -  Liver and kidney diseases&#xD;
&#xD;
          -  A person with a brain disorder, vision or hearing unusual&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Cannot follow the protocol&#xD;
&#xD;
          -  During participated in other studies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chulalongkorn University</investigator_affiliation>
    <investigator_full_name>Pornanong Aramwit, Pharm.D., Ph.D</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

